The embedded clusters DBS 77, 78, 102, and 160-161 and their link with the interstellar medium

Aims. We report a study of the global properties of some embedded clusters placed in the fourth quadrant of the Milky Way to clarify some issues related with their location into the Galaxy and their stellar formation processes. Methods. We performed BVI photometric observations in the region of DBS 77, 78, 102, 160, and 161 clusters and infrared spectroscopy in DBS 77 region. They were complemented with JHK data from VVV survey combined with 2MASS catalogue, and used mid-infrared information from GLIMPSE catalogue. We also searched for HI data from SGPS and PMN radio surveys, and previous spectroscopic stellar classification. The spectroscopic and photometric information allowed us to estimate the spectral classification of the brightest stars of each studied region. On the other hand, we used the radio data to investigate the interstellar material parameters and the continuum sources probably associated with the respective stellar components. Results. We estimated the basic physical parameters of the clusters (reddening, distance, age, and initial mass function). We searched for HII regions located near to the studied clusters and we analyzed the possible link between them. In the particular case of DBS 160-161 clusters, we identified the HI bubble B332.5-0.1-42 located around them. We found that the mechanical energy injected to the interstellar medium by the more massive stars of this couple of clusters was enough to generate the bubble.Comment: 15 pages, 14 figures, 6 tables, accepted for publication in A&

Why vitamin D for cancer patients?

Several epidemiological, pre-clinical and clinical studies support Vitamin D as a preventive and therapeutic cancer agent

A radio continuum survey of the southern sky at 1420 MHz. Observations and data reduction

We describe the equipment, observational method and reduction procedure of an absolutely calibrated radio continuum survey of the South Celestial Hemisphere at a frequency of 1420 MHz. These observations cover the area 0h < R.A. < 24h for declinations less than -10 degree. The sensitivity is about 50 mK T_B (full beam brightness) and the angular resolution (HPBW) is 35.4', which matches the existing northern sky survey at the same frequency.Comment: 9 pages with 9 figures, A&A, in pres

Networks of reliable reputations and cooperation: a review

Reputation has been shown to provide an informal solution to the problem of cooperation in human societies. After reviewing models that connect reputations and cooperation, we address how reputation results from information exchange embedded in a social network that changes endogenously itself. Theoretical studies highlight that network topologies have different effects on the extent of cooperation, since they can foster or hinder the flow of reputational information. Subsequently, we review models and empirical studies that intend to grasp the coevolution of reputations, cooperation and social networks. We identify open questions in the literature concerning how networks affect the accuracy of reputations, the honesty of shared information and the spread of reputational information. Certain network topologies may facilitate biased beliefs and intergroup competition or in-group identity formation that could lead to high cooperation within but conflicts between different subgroups of a network. Our review covers theoretical, experimental and field studies across various disciplines that target these questions and could explain how the dynamics of interactions and reputations help or prevent the establishment and sustainability of cooperation in small- and large-scale societies

The role of BRAF V600 mutation in melanoma

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib &gt;30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors

The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.

The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic treatment, whether patients with stage IIIA melanoma require adjuvant therapy or not, whether treatment is better changed at disease progression or during stable disease, whether adoptive cell transfer (ACT) therapy is more appropriate used before or in combination with checkpoint inhibition therapy, and whether treatment can be stopped while the patient is still on response. As was the case for previous meetings, the debates were assigned by meeting Chairs. As such, positions taken by each of the melanoma experts during the debates may not have reflected their respective personal approach